2021 | Israel | Randomized placebo-controlled trial
Aran A et al. Molecular Autism. 2021;12:6.
Methods: Researchers enrolled 150 participants aged 5 to 21 and tested a whole-plant extract and a purified cannabinoid mixture, each containing CBD and THC in a 20 to 1 ratio. The main efficacy comparison covered 12 weeks.
Findings: One clinician-rated primary measure favored whole-plant extract: 49% were rated much or very much improved, versus 21% with placebo. The other primary behavior questionnaire did not differ between groups. Sleepiness and reduced appetite were reported.
Limitations: The primary outcomes were inconsistent, and some assessments had missing data. The formulations included THC, so results cannot be attributed to CBD alone. Broad differences in age and functional level also limit interpretation.